The regulation of the lymphatic secretion of glucagon-like peptide-1 (GLP-1) by intestinal absorption of fat and carbohydrate

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 293, Issue 5, 2007, Pages

  Lu, Wendell J ^a   Yang, Qing ^b   Sun, William ^b   Woods, Stephen C ^a   D'Alessio, David ^a,b   Tso, Patrick ^a,b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Enteroendocrine cells; Gastrointestinal hormone secretion; Incretin; Intestinal lymph

Indexed keywords

CARBOHYDRATE; DEXTRIN; FAT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE POLYMER; INTRALIPID; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALORIC INTAKE; CARBOHYDRATE ABSORPTION; CARBOHYDRATE INTAKE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FAT INTAKE; FISTULA; HORMONAL REGULATION; HORMONE DETERMINATION; HORMONE RELEASE; HORMONE RESPONSE; IN VIVO STUDY; INTESTINE ABSORPTION; LAMINA PROPRIA; LIPID ABSORPTION; LYMPH FLOW; MALE; MESENTERY LYMPH NODE; NERVE CELL; NONHUMAN; NUTRIENT; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; STIMULATION;

ANIMALS; ANTIGENS, CD26; DEXTRINS; DIETARY CARBOHYDRATES; DIETARY FATS; FAT EMULSIONS, INTRAVENOUS; GLUCAGON-LIKE PEPTIDE 1; INTESTINAL ABSORPTION; KINETICS; LYMPHOCYTES; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 36148972789     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00146.2007     Document Type: Article

References (52)

1. Ahren B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 36: 867-876, 2004.
2. Bollman JL, Cain JC, Grindlay JH. Techniques for the collection of lymph from the liver, small intestine, or thoracic duct of the rat. J Lab Clin Med 33: 1349-1352, 1949.
3. Crapo PA, Reaven G, Olefsky JM. Plasma glucose and insulin responses to orally administered simple and complex carbohydrates. Diabetes 25: 741-747, 1976.
4. Creutzfeldt W, Nauck M. Gut hormones and diabetes mellitus. Diabetes Metab Rev 8: 149-177, 1992.
5. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80: 952-957, 1995.
6. Deacon CF, Nauck MA, Toft-Nielsen M. Both subcutaneously and intravenously administered glucagon-like peptide-1 are rapidly degraded from the NH2-terminus in type 2-diabetic patients and in healthy subjects. Diabetes 44: 1126-1131, 1995.
7. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation and apoptosis. Mol Endocrinol 17: 161-171, 2003.
8. Durinx C, Lambeir A, Bosmans E, Falmagne J, Berghmans R, Haemers A, Scharpe S, Meester ID. Molecular characterization of dipeptidyl peptidase activity in serum. Eur J Biochem 267: 5608-5613, 2000.
9. Ebert R, Creutzfeldt W. Gastrointestinal peptides and insulin secretion. Diabetes Metab Rev 3: 1-26, 1987.
10. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute postprandial and 24-h secretion patterns. J Endocrinol 138: 159-166, 1993.
11. Fehmann HC, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide. Endocr Rev 16: 390-410, 1995.
12. Fukase N, Hideo T, Igarashi M, Yamatani K, Daimon M, Sugiyama K, Tominaga Sasaki H. Differences in GLP-1 and GIP responses following sucrose ingestion. Diabetes Res Clin Pract 15: 187-195, 1992.
13. Granger DN, Taylor AE. Permeability of intestinal capillaries to endogenous macromolecules. Am J Physiol Heart Circ Physiol 238: H457-H464, 1980.
14. Green PH, Riley JW. Lipid absorption and intestinal lipoprotein formation. Aust NZ J Med 11: 84-90, 1981.
15. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1 (7-36) amide is transformed to glucagon-like peptide-1 (9-36) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140: 5356-5363, 1999.
16. Hayashi H, Nutting DF, Fujimoto K, Cardelli JA, Black D, Tso P. Transport of lipid and apolipoproteins A-I and A-IV in intestinal lymph of the rat. J Lipid Res 31: 1613-1625, 1990.
17. Herrmann C, Goke R, Richter G, Fehmann HC, Arnold R, Goke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 56: 117-126, 1995.
18. Hofmann AF, Borgstrom B. The intestinal phase of fat digestion in man: the lipid content of the micellar and oil phases of intestinal content obtained during fat digestion and absorption. J Clin Invest 43: 247-257, 1964.
19. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 47: 1663-1670, 1998.
20. Holst JJ. On the physiology of GIP and GLP-1. Horm Metab Res 36: 747-754, 2004.
21. Iritani N, Sugimoto T, Hitomi F, Masumi K, Hitoshi I. Oral triacylglycerols regulate plasma glucagon-like peptide-1(7-36) and insulin levels in normal and especially in obese rats. J Nutr 129: 46-50, 1999.
22. Jenkins DJ, Wolever TM, Leeds AR, Gassull MA, Haisman P, Dilawari J, Goff DV, Metz GL, Alberti KG. Dietary fibres, fibre analogues, and glucose tolerance: importance of viscosity. Br Med J 1: 1392-1394, 1978.
23. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 20: 876-913, 1999.
24. Kreymann B, Williams G, Ghatei M, Bloom SR. Glucagon-like peptide 7-36: a physiological incretin in man. Lancet 8571: 1300-1304, 1987.
25. McDonald GW, Fisher GF, Burnham C. Reproducibility of the oral glucose tolerance test. Diabetes 14: 473-480, 1965.
26. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214: 829-835, 1993.
27. Mojsov S, Kopczynski MG, Habener JF. Both amidated and nonamidated forms of glucagon-like peptide are synthesized in the rat intestine and the pancreas. J Biol Chem 265: 8001-8008, 1990.
28. Nagatsu T, Hinko M, Fuyamada H, Hayakawa T, Sakakibara S, Nakagawa Y, Takemoto T. New chromogenic substrates for X-prolyl dipeptidyl- aminopeptidase. Anal Biochem 74: 466-476, 1976.
29. Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 53,Suppl 3: S190-S196, 2004.
30. Nauck MA, Busing M, Orskov C, Siegel EG, Talartschik J, Baartz A, Baartz T, Holzer H, Hopt UT, Ebert R, Becker HD, Creutzfeldt W. Basal and nutrient-stimulated pancreatic and gastrointestinal hormone concentrations in type-1-diabetic patients after successful combined pancreas and kidney transplantation. Clin Investig 70: 40-48, 1992.
31. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1[7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest 91: 301-307, 1993.
32. Orskov C, Bersani M, Johnsen AJ, Hojrup R, Holst JJ. Complete sequences of glucagon-like peptide 1 from human and pig small intestine. J Biol Chem 264: 12826-12829, 1989.
33. Orskov C, Holst JJ. Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest 47: 165-174, 1987.
34. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 43: 535-539, 1994.
35. Orskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide 1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 31: 665-670, 1996.
36. Orskov C. Glucagon-like peptide 1, a new hormone of the entero-insular axis. Diabetologia 35: 701-711, 1992.
37. Ritzel U, Fromme A, Ottleben M, Leonhardt U, Ramadori G. Release of GLP-1 by carbohydrates in the perfused rat ileum. Acta Diabetol 34: 18-21, 1997.
38. Schirra J, Katschinski M, Weidman C, Schafer T, Wank U, Arnold R, Goke B. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 97: 92-103, 1996.
39. Scrocchi LA, Marshall BA, Cook SM, Brubaker PL, Drucker DJ. Glucose homeostasis in mice with disruption of GLP-1 receptor signaling. Diabetes 47: 632-639, 1998.
40. Sherman I, Dlugosz J, Barker F, Sadeghi F, Pang S. Dynamics of arterial and portal venous flow interactions in perfused rat liver: an intravital microscopic study. Am J Physiol Gastrointest Liver Physiol 271: G201-G210, 1996.
41. Sugiyama K, Manaka H, Kato T, Yamatani K, Tominaga M, Sasaki H. Stimulation of truncated glucagon-like peptide-1 release from the isolated perfused canine ileum by glucose absorption. Digestion 55: 24-28, 1994.
42. Thompson DG, Wingate DL, Thomas M, Harrison D. Gastric emptying as a determinant of the oral glucose tolerance test. Gastroenterology 82: 51-55, 1982.
43. Thomsen C, Rasmussen O, Lousen T, Holst JJ, Fenselau S, Schrezenmeir J, Hermansen K. Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects. Am J Clin Nutr 69: 1135-1143, 1999.
44. Thorne M, Thompson L, Jenkins D. Factors affecting starch digestibility and the glycemic response with special reference to legumes. Am J Clin Nutr 38: 481-488, 1983.
45. Toft-Nielsen M, Damholt MB, Madsbad S, Hilsted LM, Hughes T, Michelsen B, Holst JJ. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86: 3717-3723, 2001.
46. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 6: 24-25, 1969.
47. Tso P, Gollamudi SR. Pluronic L-81: a potent inhibitor of the transport of intestinal chylomicrons. Am J Physiol Gastrointest Liver Physiol 247: G32-G36, 1984.
48. Tso P, Balint JA, Rodgers JB. Effect of hydrophobic surfactant (Pluronic L-81) on lymphatic lipid transport in the rat. Am J Physiol Gastrointest Liver Physiol 239: G348-G353, 1980.
49. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JPH, Smith DM, Ghatei MA, Hebert J, Bloom SR. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 69-72, 1996.
50. Vahl TP, Paty BW, Fuller BD, Prigeon RL, D'Alessio DA. Effects of GLP-1-(7-36) NH2, GLP-1-(7-37), and GLP-1-(9-36) NH2 on intravenous glucose tolerance and glucose-induced insulin secretion on healthy humans. J Clin Endocrinol Metab 88: 1772-1779, 2003.
51. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Both GLP-1 and GIP are both insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 114: 115-121, 2003.
52. Wishart JM, Horowitz M, Morris HA, Jones KL, Nauck MA. Relation between gastric emptying of glucose and plasma concentrations of glucagons-like peptide-1. Peptides 19: 1049-1053, 1998.